Literature DB >> 10962203

Lecithinized copper, zinc-superoxide dismutase ameliorates prolonged hypoxia-induced injury of cardiomyocytes.

H Nakajima1, N Ishizaka, M Hangaishi, J Taguchi, J Itoh, R Igarashi, Y Mizushima, R Nagai, M Ohno.   

Abstract

Recent studies have suggested that prolonged hypoxia results in increased production of reactive oxygen species in cardiomyocytes, which leads to apoptosis of these cells. We previously showed that lecithinized recombinant human copper, zinc-superoxide dismutase (rhSOD) showed increased bioavailability through greater membrane affinity and a longer half-life than unmodified SOD. The purpose of this study was to investigate whether lecithinized SOD plays a protective role against hypoxic injury in cardiomyocytes. Cultured rat cardiomyocytes incubated with lecithinized SOD (100 U/ml), unmodified SOD (100 U/ml), or vehicle alone were subjected to hypoxia for up to 72 h. Lecithinized SOD, but not unmodified SOD, was successfully delivered intracellularly, which was verified by Western blot and confocal laser-scanning microscopy. Treatment of cells with lecithinized SOD significantly suppressed hypoxia-induced cell damage. Since lecithinized SOD also suppressed hypoxia-induced DNA fragmentation, the improved cell survival provided by lecithinized SOD is thought to be mediated by its antiapoptotic effect. In summary, lecithinization resulted in a facilitated rhSOD delivery into cultured cardiomyocytes, which reduced mortality of cardiomyocytes exposed to prolonged hypoxia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962203     DOI: 10.1016/s0891-5849(00)00290-2

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  4 in total

1.  The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man.

Authors:  F J F Broeyer; B E van Aken; J Suzuki; M J B Kemme; H C Schoemaker; A F Cohen; Y Mizushima; J Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2007-07-04       Impact factor: 4.335

2.  Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.

Authors:  Frederik J F Broeyer; Susanne Osanto; Jun Suzuki; Felix de Jongh; Henk van Slooten; Bea C Tanis; Tobias Bruning; Jeroen J Bax; Henk J Ritsema van Eck; Marieke L de Kam; Adam F Cohen; Yutaka Mituzhima; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

Review 3.  Research progress of cardioprotective agents for prevention of anthracycline cardiotoxicity.

Authors:  Jing Zhang; Xiaohai Cui; Yan Yan; Min Li; Ya Yang; Jiansheng Wang; Jia Zhang
Journal:  Am J Transl Res       Date:  2016-07-15       Impact factor: 4.060

Review 4.  Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19?

Authors:  Ilaria Farella; Raffaella Panza; Manuela Capozza; Nicola Laforgia
Journal:  Biomed Pharmacother       Date:  2021-07-14       Impact factor: 6.529

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.